Fluoxetine Induces Hepatic Lipid Accumulation Via Both Promotion of the SREBP1c-Related Lipogenesis and Reduction of Lipolysis in Primary Mouse Hepatocytes

CNS Neuroscience and Therapeutics

Volumn 18, Issue 12, 2012, Pages 974-980

  Feng, Xue Min ^a   Xiong, Jing ^a   Qin, Hao ^a   Liu, Wei ^a   Chen, Rui Ni ^a   Shang, Wei ^a   Ning, Rui ^a   Hu, Gang ^a   Yang, Jian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Carboxylesterase; Fluoxetine (FLX); Hepatocyte; Lipid accumulation; Triglyceride

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 3; FATTY ACID SYNTHASE; FLUOXETINE; MITOGEN ACTIVATED PROTEIN KINASE P38; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETYLTRANSFERASES; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD95; CARBOXYLIC ESTER HYDROLASES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUOXETINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED ICR; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84870402499     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12014     Document Type: Article

References (46)

1. Insel TR, Charney DS. Research on major depression: strategies and priorities. JAMA 2003;289:3167-3168.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
4. Freeborough A, Kimpton J. Discovering new genetic and psychosocial pathways in Major Depressive Disorder: the NewMood project. Psychiatr Danub 2011;23(Suppl 1):S138-S141.
5. Asarnow JR, Emslie G, Clarke G, et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009;48:330-339.
6. Severus E, Schaaff N, Möller HJ. State of the art: treatment of bipolar disorders. CNS Neurosci Ther 2012;18:214-218.
7. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005;4:764-774.
8. Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011;17:750-760.
9. Mastronardi C, Paz-Filho GJ, Valdez E, Maestre-Mesa J, Licinio J, Wong ML. Long-term body weight outcomes of antidepressant-environment interactions. Mol Psychiatry 2011;16:265-272.
10. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42:192-198.
11. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002;14:175-182.
12. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009;6:16-18.
13. Warden D, Trivedi MH, Wisniewski SR, et al. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol 2010;30:259-266.
14. Yang LH, Chen TM, Yu ST, Chen YH. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007;56:202-208.
15. Menendez JA, Vazquez-Martin A, Ortega FJ, Fernandez-Real JM. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009;55:425-438.
16. Cheng D, Chu CH, Chen L, et al. Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes. Protein Expr Purif 2007;51:11-21.
17. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010;12(Suppl 2):83-92.
18. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131.
19. Quiroga AD, Lehner R. Liver triacylglycerol lipases. Biochim Biophys Acta 2012;1821:762-769.
20. Reid BN, Ables GP, Otlivanchik OA, et al. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 2008;283:13087-13099.
21. Cygler M, Schrag JD, Sussman JL, et al. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins. Protein Sci 1993;2:366-382.
22. Mao Z, Li Y, Peng Y, et al. Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-kappaB pathway. Toxicol Lett 2011;201:213-220.
23. Dolinsky VW, Gilham D, Alam M, Vance DE, Lehner R. Triacylglycerol hydrolase: role in intracellular lipid metabolism. Cell Mol Life Sci 2004;61:1633-1651.
24. Ko KW, Erickson B, Lehner R. Es-x/Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes. Biochim Biophys Acta 2009;1791:1133-1143.
25. Severgnini M, Sherman J, Sehgal A, et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. Cytotechnology 2012;64:187-195.
26. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 1974;15:471-479.
27. Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006;395:185-190.
28. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-856.
29. Kivimaki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010;33:2611-2616.
30. Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev 2004;5:167-170.
31. Fride E, Bregman T, Kirkham TC. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 2005;230:225-234.
32. Turner EH, Rosenthal R. Efficacy of antidepressants. BMJ 2008;336:516-517.
33. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260.
34. Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005;62:1784-1803.
35. Sato R. SREBPs: protein interaction and SREBPs. FEBS J 2009;276:622-627.
36. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002;366:377-391.
37. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-340.
38. Lauressergues E, Staels B, Valeille K, et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 2010;381:427-439.
39. Ferno J, Vik-Mo AO, Jassim G, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009;203:73-84.
40. Lin ML, Lu YC, Chung JG, et al. Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 2010;49:783-797.
41. Mazzone GL, Rigato I, Ostrow JD, Tiribelli C. Bilirubin effect on endothelial adhesion molecules expression is mediated by the NF-kappaB signaling pathway. Biosci Trends 2009;3:151-157.
42. Peterson JM, Aja S, Wei Z, Wong GW. CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem 2012;287:1576-1587.
43. Ross MK, Crow JA. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 2007;21:187-196.
44. Xiao D, Chen YT, Yang D, Yan B. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol 2012;84:232-239.
45. Zhu HJ, Appel DI, Peterson YK, Wang ZC, Markowitz JS. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 2010;270:59-65.
46. Abu-Elheiga L, Almarza-Ortega DB, Baldini A, Wakil SJ. Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. J Biol Chem 1997;272:10669-10677.